All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F20%3A43919613" target="_blank" >RIV/62156489:43210/20:43919613 - isvavai.cz</a>

  • Result on the web

    <a href="https://mnet.mendelu.cz/mendelnet2020/mnet_2020_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2020/mnet_2020_full.pdf</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells

  • Original language description

    Metallothionein (MT) expression has been tied to drug resistance in cancer cells. The MT isoforms have also been investigated in connection to tyrosine kinase inhibitor (TKI) treatment - especially with sorafenib. Our work is focused on three different TKIs - vandetanib, lenvatinib and cabozantinib. Our aim was to investigate the effect of these TKIs on the expression of MT isoforms in breast cancer cell lines. We performed gene expression analysis of seven MT isoforms after TKI treatment. The analysis revealed that each TKI had a different impact on each cell line. Cabozantinib seemed to induce the biggest response of MT expression out of the three inhibitors, with fold change of MT1F and MT1G reaching 1.68 and 1.62, respectively, in MDA-MB-468 after 24h treatment. Lenvatinib, on the other hand, downregulated MT1X in the same cell line after 72h 0.48-fold. Similarly to MDA-MB-468, cabozantinib treatment upregulated MT1E and MT1X in MDA-MB-231 after 72h treatment, with 1.68 and 1.87-fold difference, respectively.

  • Czech name

  • Czech description

Classification

  • Type

    D - Article in proceedings

  • CEP classification

  • OECD FORD branch

    10608 - Biochemistry and molecular biology

Result continuities

  • Project

    <a href="/en/project/GA18-10251S" target="_blank" >GA18-10251S: Comprehensive insight into mechanisms of action and metabolism of tyrosine kinase inhibitors and a study of ways increasing their antitumor efficiency</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Article name in the collection

    MendelNet 2020: Proceedings of International PhD Students Conference

  • ISBN

    978-80-7509-765-1

  • ISSN

  • e-ISSN

  • Number of pages

    5

  • Pages from-to

    562-566

  • Publisher name

    Mendelova univerzita v Brně

  • Place of publication

    Brno

  • Event location

    Brno

  • Event date

    Nov 11, 2020

  • Type of event by nationality

    WRD - Celosvětová akce

  • UT code for WoS article